These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35747980)

  • 1. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
    Gill J
    Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Toxicities of CAR T-cell Therapy.
    Patel NP; Doukas PG; Gordon LI; Akhter N
    Curr Oncol Rep; 2021 May; 23(7):78. PubMed ID: 33937946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
    Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
    J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
    J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
    Guo M; Wang X; Xiao S; Liu A; Xu T; Huan C; Wu H; Hu Y; Zhou S; Zhu H; Pan D
    Clin Exp Med; 2023 Oct; 23(6):2041-2050. PubMed ID: 36930381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
    Jamal FA; Khaled SK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
    Totzeck M; Michel L; Lin Y; Herrmann J; Rassaf T
    Eur Heart J; 2022 May; 43(20):1928-1940. PubMed ID: 35257157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
    Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
    Ghosh AK; Chen DH; Guha A; Mackenzie S; Walker JM; Roddie C
    JACC CardioOncol; 2020 Mar; 2(1):97-109. PubMed ID: 34396213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
    Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
    Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
    Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
    BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
    Chen HH; Kuo CY; Ho CL; Chen YC
    Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
    Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
    J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
    Taheri S
    Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.